Marketing-authorisation holder · United States
Cheplapharm
14 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
14 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
14 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CYTOVENE500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Ganciclovir | United States | Not marketed | 1989 |
| KLONOPIN0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 0.5MG | 1MG | 2MG · Tablet | Clonazepam | United States | Marketed | 1975 |
| PULMICORT FLEXHALER0.08mg/inh | 0.16mg/inh · Powder, metered | Budesonide | United States | Marketed | 2006 |
| SEROQUEL100MG BASE | 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 200MG BASE | 25MG BASE | 300MG BASE | 400MG BASE | 50MG BASE · Tablet | Quetiapine | United States | Marketed | 1997 |
| SEROQUEL XR150mg base | 200mg | 200mg base | 300mg | 300mg base | 400mg | 400mg base | 50mg | 50mg base · Tablet, extended release | Quetiapine | United States | Marketed | 2007 |
| VALCYTE450mg base · Tablet | Valganciclovir | United States | Marketed | 2001 |
| VALCYTE50mg/ml · For solution | Valganciclovir | United States | Marketed | 2009 |
| VESANOID10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Tretinoin | United States | Not marketed | 1995 |
| XELODA150mg | 500mg · Tablet | Capecitabine | United States | Not marketed | 1998 |
| XENICAL120mg · Capsule | Orlistat | United States | Marketed | 1999 |
| ZYPREXA10mg/vial · Powder | Olanzapine | United States | Marketed | 2004 |
| ZYPREXA10mg | 15mg | 2.5mg | 20mg | 5mg | 7.5mg · Tablet | Olanzapine | United States | Marketed | 1996 |
| ZYPREXA RELPREVV210mg base/vial | 300mg base/vial | 405mg base/vial · Suspension, extended release | Olanzapine | United States | Marketed | 2009 |
| ZYPREXA ZYDIS10mg | 15mg | 20mg | 5mg · Tablet, orally disintegrating | Olanzapine | United States | Marketed | 2000 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 14 | 14 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.